Published in:
Open Access
01-02-2011 | Poster presentation
Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation
Authors:
N Harayama, S Nihei, Y Isa, H Arai, T Shinjou, K Nagata, M Ueki, K Aibara, M Kamochi
Published in:
Critical Care
|
Special Issue 1/2011
Login to get access
Excerpt
Nifekalant (NIF) is a pure potassium channel blocker developed in Japan and it has been used widely for treating fatal ventricular tachyarrhythmia since 1999. Because intravenous amiodarone (AMD) was approved in 2007 in Japan, there have been few studies about the comparison of the efficacy of NIF and AMD for resuscitation after cardiopulmonary arrest patients due to shock-resistant ventricular fibrillation. …